Egyptian vaccine manufacturer Vaxciera has highlighted the need for comprehensive protection against meningitis, stating that its quadravaccine does not provide immunity against all strains, particularly type B. The company emphasized that its quadravaccine protects against strains A, C, W, and Y, but not type B, which requires a separate vaccine. This underscores the importance of administering both vaccines to ensure complete protection for children and young adults.
Vaxciera's quadravaccine and type B meningitis vaccine are designed to be complementary, not interchangeable. The type B vaccine is recommended for individuals aged 2 months to 50 years, with a particular emphasis on vaccinating children and adolescents due to their higher exposure risk. The company stressed that receiving both vaccines is crucial for safeguarding against the severe consequences of meningitis.
The type B meningitis vaccine requires two or three doses, depending on the recipient's age and health status. Vaxciera noted that the vaccine's side effects are typically mild and temporary, including slight fever elevation and localized pain at the injection site. These reactions are indicative of the body's immune response and are generally short-lived.
Vaxciera assured that its vaccines are readily available at its serum and vaccine centers nationwide. The company urged parents to complete the necessary vaccination schedules to protect their children from the serious complications of meningitis. By doing so, parents can ensure their children receive the full benefits of immunization.
According to Vaxciera, investing in preventive measures is the safest option, particularly when it comes to children's health. The company operates under the motto "Your health is a trust," emphasizing its commitment to safeguarding public health through vaccination.
The Egyptian healthcare sector continues to prioritize vaccination programs, with Vaxciera playing a significant role in these efforts. By providing essential vaccines, the company aims to reduce the incidence of meningitis and promote overall well-being among the population.
Vaxciera's efforts to raise awareness about the importance of meningitis vaccination are ongoing. The company collaborates with healthcare professionals and organizations to educate the public about the risks associated with meningitis and the benefits of immunization.
Key points
- Vaxciera's quadravaccine does not protect against type B meningitis, requiring a separate vaccine for comprehensive protection.
- The type B meningitis vaccine is recommended for individuals aged 2 months to 50 years, with a focus on children and adolescents.
- Vaxciera's vaccines are available at its serum and vaccine centers nationwide, with the company encouraging parents to complete vaccination schedules to safeguard their children's health.
